Drugs / HL-1186
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06912295 | Mar → Aug 2025 overdue | — | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07311369 | Dec 2025 → Feb 2026 overdue | — | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07159243 | Sep 2025 → Oct 2026 expected | diabetic polyneuropathy | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07147049 | Aug → Dec 2025 overdue | — | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07709598 | May → Oct 2026 expected | — | Shanghai Huilun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07699601 | May → Oct 2026 expected | — | Shanghai Huilun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL-1186 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709598 ↗ |
| Route | Oral | “HL-1186 tablet for oral administration.” NCT06912295 ↗ |